Literature DB >> 25372658

Clinical presentation of patients with Ebola virus disease in Conakry, Guinea.

Elhadj Ibrahima Bah1, Marie-Claire Lamah, Tom Fletcher, Shevin T Jacob, David M Brett-Major, Amadou Alpha Sall, Nahoko Shindo, William A Fischer, Francois Lamontagne, Sow Mamadou Saliou, Daniel G Bausch, Barry Moumié, Tim Jagatic, Armand Sprecher, James V Lawler, Thierry Mayet, Frederique A Jacquerioz, María F Méndez Baggi, Constanza Vallenas, Christophe Clement, Simon Mardel, Ousmane Faye, Oumar Faye, Baré Soropogui, Nfaly Magassouba, Lamine Koivogui, Ruxandra Pinto, Robert A Fowler.   

Abstract

BACKGROUND: In March 2014, the World Health Organization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea. The outbreak then spread to the capital, Conakry, and to neighboring countries and has subsequently become the largest epidemic of Ebola virus disease (EVD) to date.
METHODS: From March 25 to April 26, 2014, we performed a study of all patients with laboratory-confirmed EVD in Conakry. Mortality was the primary outcome. Secondary outcomes included patient characteristics, complications, treatments, and comparisons between survivors and nonsurvivors.
RESULTS: Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD. Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46), 24 patients (65%) were men, and 14 (38%) were health care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (32%). Patients with confirmed EVD presented to the hospital a median of 5 days (interquartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in 84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%), and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%) were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7 to 11). Patients who were 40 years of age or older, as compared with those under the age of 40 years, had a relative risk of death of 3.49 (95% confidence interval, 1.42 to 8.59; P=0.007).
CONCLUSIONS: Patients with EVD presented with evidence of dehydration associated with vomiting and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and limited laboratory services, the rate of death was 43%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372658     DOI: 10.1056/NEJMoa1411249

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  146 in total

1.  Vitamin A Supplementation Was Associated with Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak.

Authors:  Adam R Aluisio; Shiromi M Perera; Derrick Yam; Stephanie Garbern; Jillian L Peters; Logan Abel; Daniel K Cho; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Suzanne Brinkmann; Lindsey Locks; Tao Liu; Adam C Levine
Journal:  J Nutr       Date:  2019-10-01       Impact factor: 4.798

2.  A mechanistic spatio-temporal framework for modelling individual-to-individual transmission-With an application to the 2014-2015 West Africa Ebola outbreak.

Authors:  Max S Y Lau; Gavin J Gibson; Hola Adrakey; Amanda McClelland; Steven Riley; Jon Zelner; George Streftaris; Sebastian Funk; Jessica Metcalf; Benjamin D Dalziel; Bryan T Grenfell
Journal:  PLoS Comput Biol       Date:  2017-10-30       Impact factor: 4.475

3.  Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.

Authors:  Szu-Yuan Pu; Randy Wouters; Stanford Schor; Jef Rozenski; Rina Barouch-Bentov; Laura I Prugar; Cecilia M O'Brien; Jennifer M Brannan; John M Dye; Piet Herdewijn; Steven De Jonghe; Shirit Einav
Journal:  J Med Chem       Date:  2018-07-16       Impact factor: 7.446

4.  A Health Care Worker with Ebola Virus Disease and Adverse Prognostic Factors Treated in Sierra Leone.

Authors:  Matthew K O'Shea; Katherine A Clay; Darren G Craig; Alastair J Moore; Stephen Lewis; Melanie Espina; Jeff Praught; Simon Horne; Raymond Kao; Andrew M Johnston
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

5.  Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type.

Authors:  Sophie J Smither; Simon A Weller; Amanda Phelps; Lin Eastaugh; Sarah Ngugi; Lyn M O'Brien; Jackie Steward; Steve G Lonsdale; Mark S Lever
Journal:  J Clin Microbiol       Date:  2015-07-15       Impact factor: 5.948

Review 6.  Ebola virus disease.

Authors:  Nicholas J Beeching; Manuel Fenech; Catherine F Houlihan
Journal:  BMJ       Date:  2014-12-10

7.  Laboratory diagnosis of Ebola virus disease.

Authors:  Philippe Martin; Kevin B Laupland; Eric H Frost; Louis Valiquette
Journal:  Intensive Care Med       Date:  2015-01-31       Impact factor: 17.440

8.  Impact of Intravenous Fluid Therapy on Survival Among Patients With Ebola Virus Disease: An International Multisite Retrospective Cohort Study.

Authors:  Adam R Aluisio; Derrick Yam; Jillian L Peters; Daniel K Cho; Shiromi M Perera; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Michael A Smit; Tao Liu; Adam C Levine
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

9.  Clinical presentation of pregnant women in isolation units for Ebola virus disease in Sierra Leone, 2014.

Authors:  Jonetta J Mpofu; Fatma Soud; Meghan Lyman; Alimamy P Koroma; Diane Morof; Sascha Ellington; Samuel S Kargbo; William Callaghan
Journal:  Int J Gynaecol Obstet       Date:  2019-02-14       Impact factor: 3.561

Review 10.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.